EFM-192AHomo sapiens (Human)Cancer cell line

Also known as: EFM192, EFM192A

🤖 AI SummaryBased on 7 publications

Quick Overview

Human breast cancer cell line for cancer research and drug development.

Detailed Summary

EFM-192A is a human breast cancer cell line derived from a primary tumor. It is used in research to study cancer biology, drug sensitivity, and therapeutic responses. The cell line is part of large-scale studies that analyze genomic and transcriptomic data to identify potential targets for cancer treatment. EFM-192A is utilized in investigations related to gene expression, mutations, and protein interactions to understand cancer progression and develop targeted therapies. Its characteristics make it a valuable model for studying breast cancer mechanisms and evaluating new treatment strategies.
Generated on 6/17/2025

Basic Information

Database IDCVCL_1812
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age46
Age CategoryAdult
SexFemale
Racecaucasian
Subtype FeaturesHER2+

Disease Information

DiseaseBreast carcinoma
LineageBreast
SubtypeInvasive Breast Carcinoma
OncoTree CodeBRCA

DepMap Information

Source TypeDSMZ
Source IDACH-000117_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Glu271fs*1 (c.807_808insT)Heterozygous-Unknown, Unknown
MutationSimplePIK3CAp.Cys420Arg (c.1258T>C)Heterozygous-from parent cell line JIMT-1

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12,13
D13S317
9,14
D16S539
8,13
D18S51
17
D19S433
14
D21S11
32.2
D2S1338
17,25
D3S1358
16
D5S818
12,13
D7S820
8,11
D8S1179
9,15
FGA
20,22
Penta D
9
Penta E
14,16
TH01
7
TPOX
8,10
vWA
16
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

OncoImmunology 3:e954893.1-e954893.12(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Modeling precision treatment of breast cancer.";

Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.

Genome Biol. 14:R110.1-R110.14(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.

Pollack J.R.

PLoS ONE 4:E6146-E6146(2009).

Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.

Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.

Cancer Res. 60:4519-4525(2000).